Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.74 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.73 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.73 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.73 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.73 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.73 |
| ▸ | SLC6A5 | Q9Y345 | 4/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6839077 | 1.00 | SLC18A3 (0.74) | SLC18A3OPRM1OPRL1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL7709374 | 0.99 | SLC18A3 (0.72) | SLC18A3OPRM1OPRL1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL7703755 | 0.99 | SLC18A3 (0.72) | SLC18A3OPRM1OPRL1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL7706463 | 0.99 | SLC18A3 (0.72) | SLC18A3OPRM1OPRL1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL7706445 | 0.99 | SLC18A3 (0.72) | SLC18A3OPRM1OPRL1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL7709447 | 0.99 | SLC18A3 (0.72) | SLC18A3OPRM1OPRL1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL7706374 | 0.99 | SLC18A3 (0.72) | SLC18A3OPRM1OPRL1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL7703785 | 0.99 | SLC18A3 (0.72) | SLC18A3OPRM1OPRL1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL7707065 | 0.92 | SLC18A3 (0.67) | SLC18A3OPRM1OPRL1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL7707063 | 0.92 | SLC18A3 (0.67) | SLC18A3OPRM1OPRL1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0921125-B1 | 1,3,8-Triazaspiro[4,5]decan-4-on derivatives | HOFFMANN LA ROCHE (CH) | 2002-01-30 | — | — | EP | claimed |
| EP-0921125-A1 | 1,3,8-Triaza-spiro 4,5 decan-4-on derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-06-09 | — | — | EP | claimed |
| US-20040067950-A1 | High affinity ligands for nociceptin receptor ORL-1 | SCHERING-PLOUGH CORPORATION | 2004-04-08 | — | — | US | disclosed |
| EP-1200087-A1 | NOCICEPTIN RECEPTOR ORL-1 AGONISTS FOR USE IN TREATING COUGH | SCHERING CORPORATION (US) | 2002-05-02 | — | — | EP | disclosed |
| EP-0921125-B1 | 1,3,8-Triazaspiro[4,5]decan-4-on derivatives | HOFFMANN LA ROCHE (CH) | 2002-01-30 | — | — | EP | disclosed |
| WO-2001007050-A1 | NOCICEPTIN RECEPTOR ORL-1 AGONISTS FOR USE IN TREATING COUGH | SCHERING CORPORATION (US) | 2001-02-01 | — | — | WO | disclosed |
| US-6043366-A | USEFUL IN TREATING DISORDERS INVOLVING THE ORPHANIN FQ(A SEVENTEEN AMINO ACID LONG PEPTIDE) RECEPTOR. | HOFFMAN-LA ROCHE INC. (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0921125-A1 | 1,3,8-Triaza-spiro 4,5 decan-4-on derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067950-A1 | High affinity ligands for nociceptin receptor ORL-1 | OPRL1, OPRD1, OGFRL1 | SLC18A3 1514/4885OPRM1 5/4885OPRL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.